Previous 10 | Next 10 |
The following slide deck was published by Madrigal Pharmaceuticals, Inc. in conjunction with this event. For further details see: Madrigal Pharmaceuticals (MDGL) Investor Presentation - Slideshow
CONSHOHOCKEN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today announced its support for the fifth International NASH Day, taking place ...
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investo...
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor c...
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2022 Results Earnings Conference Call May 09, 2022, 08:00 AM ET Company Participants Paul Friedman - Chairman and Chief Executive Officer Rebecca Taub - Founder, Chief Medical Officer and President of Research & Development Remy Sukhija - Chief Com...
Madrigal Pharmaceuticals press release (NASDAQ:MDGL): Q1 GAAP EPS of -$3.36 beats by $0.20. As of March 31, 2022, Madrigal had cash, cash equivalents and marketable securities of $220.0 million, compared to $270.3 million at December 31, 2021. Operating expenses were $57.6 million for t...
MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™ Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetirom Madrigal remai...
ACM,ADAP,APRN,AUD,AVDL,AZUL,BLDP,BNTX,BTAI,COTY,DTIL,DUK,EGRX,ELAN,ENR,FOLD,GSL,HEP,HGV,JLL,KNDI,KOS,LINC,MAC,MDGL,MRSN,MSGE,MTBC,OSG,PLTR,PRTY,RCM,RIDE,SPTN,TGNA,THS,TSN,VRTV,VTRS,WOW,WTRG For Seeking Alpha's full earnings season calendar, click here. For further details see: Nota...
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, May 9, 2022 a...
Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 (MAESTRO-NASH) trial. Despite strong funda...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...